Lumbreras-Iglesias Pilar, Rodicio María Rosario, Valledor Pablo, Suárez-Zarracina Tomás, Fernández Javier
Department of Clinical Microbiology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Traslational Microbiology Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Antibiotics (Basel). 2021 Sep 27;10(10):1174. doi: 10.3390/antibiotics10101174.
The aim of this work was to analyze outer membrane porin-encoding genes ( and ) in a collection of OXA-48 producing , to assess the effect of porin alterations on the susceptibility to ceftazidime/avibactam, and to describe a screening methodology for phenotypic detection of OXA-48-producing with disrupted porins. Antimicrobial susceptibility was tested by Microscan and Etest. The genomes of 81 OXA-48-producing were sequenced. MLST, detection of antimicrobial resistance genes, and analysis of and were performed . Tridimensional structures of the OmpK36 variants were assessed. Receiver operating characteristics curves were built to visualize the performance ability of a disk diffusion assay using carbapenems and cefoxitin to detect OmpK36 functional alterations. A wide variety of OmpK36 alterations were detected in 17 OXA-48-producing isolates. All displayed a high-level meropenem resistance (MIC ≥ 8 mg/L), and some belonged to high-risk clones, such as ST15 and ST147. Alterations in were also observed, but they did not correlate with high-level meropenem resistance. All isolates were susceptible to ceftazidime/avibactam and porin alterations did not affect the MICs of the latter combination. Cefoxitin together with ertapenem/meropenem low inhibition zone diameters (equal or lower than 16 mm) could strongly suggest alterations affecting OmpK36 in OXA-48-producing . OXA-48-producing with porin disruptions are a cause of concern; ceftazidime/avibactam showed good activity against them, so this combination could be positioned as the choice therapy to combat the infections caused by this difficult-to-treat isolates.
本研究旨在分析产OXA-48菌株中编码外膜孔蛋白的基因(和),评估孔蛋白改变对头孢他啶/阿维巴坦敏感性的影响,并描述一种用于表型检测产OXA-48且孔蛋白破坏菌株的筛选方法。采用Microscan和Etest检测抗菌药物敏感性。对81株产OXA-48菌株的基因组进行测序。进行多位点序列分型、抗菌药物耐药基因检测以及和的分析。评估OmpK36变体的三维结构。构建受试者工作特征曲线以观察使用碳青霉烯类和头孢西丁的纸片扩散法检测OmpK36功能改变的性能。在17株产OXA-48菌株分离株中检测到多种OmpK36改变。所有菌株均表现出对美罗培南的高水平耐药(MIC≥8mg/L),部分属于高危克隆,如ST15和ST147。也观察到的改变,但它们与美罗培南高水平耐药无关。所有分离株对头孢他啶/阿维巴坦敏感,孔蛋白改变不影响后者组合的MIC值。头孢西丁与厄他培南/美罗培南的低抑菌圈直径(等于或低于16mm)强烈提示产OXA-48菌株中影响OmpK36的改变。孔蛋白破坏的产OXA-48菌株令人担忧;头孢他啶/阿维巴坦对它们显示出良好的活性,因此该组合可作为治疗由这种难治性分离株引起感染的首选疗法。